Darolutamide Slows Metastasis in Prostate Cancer
- PMID: 30824428
- DOI: 10.1158/2159-8290.CD-NB2019-029
Darolutamide Slows Metastasis in Prostate Cancer
Abstract
The phase III ARAMIS study shows that the androgen-receptor antagonist darolutamide delays metastasis in men with castration-resistant prostate cancer by a median of 22 months compared with a placebo. Researchers also found that side effects associated with other drugs in this class were no more common in the placebo group than the darolutamide group.
©2019 American Association for Cancer Research.
Comment on
-
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. N Engl J Med. 2019. PMID: 30763142 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources